Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-16 of 16 for your search:
Drug:
ABT-888
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of ABT-888, Cyclophosphamide With Versus Without Doxorubicin Hydrochloride in Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CINJ-050803
, 050803, 7998, NCT00740805
2.
Phase I/II Study of ABT-888 in Combination With Radiotherapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
ABTC-0801
, NABTT-0801, 0801, ABBOTT-M10-190, NCT00770471
3.
Phase I/II Study of ABT-888 and Topotecan Hydrochloride in Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0861
, MC0861, 8329, NCT01012817
4.
Phase I/II Randomized Study of ABT-888 and Temozolomide in Patients With Recurrent Glioblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0929
, RTOG-0929, NCT01026493
5.
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
097517
, NCT01042379
6.
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
2009-170
, NCT01051596
7.
Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Patients With Advanced or Refractory Solid Tumors, Lymphoma, or Chronic Lymphocytic Leukemia
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0203
, P7241, 7981, NCT00553189
8.
Phase I Study of ABT-888, Carboplatin, and Paclitaxel in Patients With Advanced Solid Malignancies
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PCI-07-015
, 07-015, 7967, NCT00535119
9.
Phase I Study of ABT-888 and Topotecan Hydrochloride With or Without Carboplatin in Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0783
, J0783, 7968, NCT00588991
10.
Phase I Study of Irinotecan Hydrochloride and ABT-888 in Patients With Metastatic or Unresectable Malignancies
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
WSU-2007-014
, 2007-014, 7977, NCT00576654
11.
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
M10-128
, NCT00649207
12.
Phase I Study of ABT-888 and Metronomic Cyclophosphamide in Patients With Refractory Solid Tumors or Lymphoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-09-C-0048
, 09-C-0048, 8275, P8437, NCT00810966
13.
Phase I Study of ABT-888 in Patients With Refractory BRCA1/2-Mutated Malignant Solid Tumors, Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, or Basal-Like Breast Cancer
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UPCI 08-121
, UPCI 08-121, 8282, NCT00892736, CINJ-050810
14.
Phase I Study of ABT-888 and Temozolomide in Pediatric Patients With Recurrent or Refractory CNS Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-027
, PBTC-027, NCT00946335
15.
Phase I Study of Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
GOG-9923
, GOG-9923, NCT00989651
16.
Phase I Study of ABT-888 With or Without Mitomycin C in Patients With Metastatic, Unresectable, or Recurrent Solid Tumors With A Deficiency in Homologous Recombination Repair
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
OSU-09100
, OSU 09100, 8472, NCT01017640
Select All on Page
Help with Results
